Zhifei Biotech: Adjusts Strategic Cooperation Agreement with Merck & Co.

Zhifei Biotech announces that the company and Merck & Co. signed the “Amended and Restated Supply, Distribution, and Co-Promotion Agreement” on April 2, 2026, which terminates the original agreement from the effective date of the new agreement.
The new agreement aims to deepen strategic cooperation between both parties, enhance market synergy and response capabilities, and alleviate the company’s operational pressure.
The products covered by the agreement include the nine-valent HPV vaccine and others, with a cooperation period until the end of 2028, extendable by two years.
The company will dynamically adjust procurement and supply volumes based on market demand, and the performance of the agreement will be disclosed periodically.
The new agreement no longer stipulates a basic procurement amount for the agreement products; the company and Merck & Co. will negotiate and confirm expected procurement and supply plans based on market demand forecasts and actual vaccination situations, and the company will conduct rolling procurement of the agreement products accordingly.
The specific procurement details shall be subject to written orders confirmed by both parties.